NewAmsterdam Pharma Co N.V.

NewAmsterdam Pharma Co N.V. (NAMS) has reported zero cyber incidents and zero red-flag 8-K filings over the past 90 days, indicating a stable recent period on the compliance and security front. However, low signal in our 90-day window does not mean low risk; the full Report pulls 12 months of filing history and adds dilution risk scoring, historical 8-K context, equity financing patterns, and AI-detected risk signals that may not yet be visible in recent filings. The full $49 Report adds a complete dilution trajectory, institutional financing trends, and forward-looking risk assessment across governance, capital structure, and operational risk factors.